Systemic Lupus Erthematosus (SLE)
12
8
8
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (12)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis
Effect of Anti-inflammatory Diet in Systemic Lupus Erythematous
2-HOBA in Systemic Lupus Erythematosus
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
KN5501 Cell Injection for Refractory SLE(CLEAR)
Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy